Cerus Corp
F:CU2
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
C
|
Cerus Corp
F:CU2
|
US |
|
E
|
Ecarx Holdings Inc.
NASDAQ:ECX
|
CN |
|
G
|
Gladstone Capital Corp
NASDAQ:GLAD
|
US |
|
M
|
Morgan Stanley
XMUN:DWD
|
US |
|
Hydrix Ltd
ASX:HYD
|
AU |
|
A
|
Airbus SE
XMUN:AIR
|
NL |
Ergebniskonferenzen
Letzter Earnings Call
Revenue: Cerus posted second-quarter product revenue of $57.4 million, up 10% year over year, and said demand remained strong across product categories.
Guidance: Management raised full-year 2026 product revenue guidance to $229 million to $231 million and lifted IFC revenue guidance to $23 million to $25 million.
IFC Growth: U.S. IFC revenue reached $6.7 million, and management said kit adoption, BCA partnerships, and hospital activations are driving momentum.
Margins: Product gross margin was 51.4%, pressured by a stronger euro and inflation, but management still expects 2026 gross margins to stay in the low 50s.
Pipeline: Cerus submitted the INT200 platelet PMA to the FDA and remains on track for top-line RedeS red blood cell data in the fourth quarter.
Balance Sheet: A debt refinancing reduced term debt by $30 million and is expected to cut annual interest expense by up to $3.5 million.